Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Sex Transm Dis. 2010 May;37(5):290–297. doi: 10.1097/OLQ.0b013e3181d3d023

Figure 3.

Figure 3

Impact of mass vaccination in diverse HSV-2 settings having the same hierarchy of sexual risk as in Kisumu, Kenya. (A) Number of vaccination procedures needed per each HSV-2 infection averted at varying baseline HSV-2 prevalence levels before vaccine administration. (B) HSV-2 excess prevalence at endemic equilibrium (prevalence post-intervention subtracted from prevalence pre-intervention) at varying HSV-2 baseline prevalence levels. Vaccine properties are as in Figure 2.